MA53706A - Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne - Google Patents
Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienneInfo
- Publication number
- MA53706A MA53706A MA053706A MA53706A MA53706A MA 53706 A MA53706 A MA 53706A MA 053706 A MA053706 A MA 053706A MA 53706 A MA53706 A MA 53706A MA 53706 A MA53706 A MA 53706A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- bacterial infection
- indane derivatives
- indane
- derivatives
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 150000002468 indanes Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18290106.6A EP3628666A1 (fr) | 2018-09-25 | 2018-09-25 | Dérivés d'indane pour le traitement des infections bactériennes |
| EP18290104 | 2018-09-26 | ||
| EP18197365 | 2018-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53706A true MA53706A (fr) | 2021-12-29 |
Family
ID=67439236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053706A MA53706A (fr) | 2018-09-25 | 2019-07-25 | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne |
| MA053707A MA53707A (fr) | 2018-09-25 | 2019-07-25 | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053707A MA53707A (fr) | 2018-09-25 | 2019-07-25 | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210347748A1 (fr) |
| EP (2) | EP3856729A1 (fr) |
| JP (2) | JP7429992B2 (fr) |
| KR (2) | KR20210087025A (fr) |
| CN (2) | CN113166084B (fr) |
| AU (2) | AU2019351551A1 (fr) |
| BR (2) | BR112021005651A2 (fr) |
| CA (2) | CA3113689A1 (fr) |
| CL (2) | CL2021000729A1 (fr) |
| IL (2) | IL281770A (fr) |
| MA (2) | MA53706A (fr) |
| MX (2) | MX2021003498A (fr) |
| SG (2) | SG11202102791SA (fr) |
| WO (2) | WO2020064173A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7429992B2 (ja) * | 2018-09-25 | 2024-02-09 | アンタビオ エスアーエス | 細菌感染の処置における使用のためのインダン誘導体 |
| EP4125883A1 (fr) * | 2020-03-24 | 2023-02-08 | Antabio SAS | Polythérapie |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457196A (en) * | 1991-09-27 | 1995-10-10 | Merrell Dow Pharmaceuticals Inc. | 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
| JP3126541B2 (ja) * | 1993-03-26 | 2001-01-22 | 千寿製薬株式会社 | ベンゾチアゾール誘導体、その製法及びその用途 |
| JPH0782259A (ja) * | 1993-09-14 | 1995-03-28 | Senju Pharmaceut Co Ltd | スクシンアミド酸誘導体及びそれを含有する糖尿病合併症治療剤 |
| JPH11130761A (ja) * | 1997-10-24 | 1999-05-18 | Otsuka Pharmaceut Co Ltd | ベンゾチアゾール誘導体 |
| US7659300B2 (en) | 2004-09-08 | 2010-02-09 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirolactam CGRP receptor antagonists |
| FR2883876B1 (fr) | 2005-03-30 | 2007-05-04 | Servier Lab | Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JP5028413B2 (ja) | 2005-05-25 | 2012-09-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピラン−ジオキサン誘導体類、および液晶媒体中におけるそれの使用 |
| MX2009011615A (es) | 2007-06-05 | 2009-11-10 | Sanofi Aventis | Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados. |
| EP2141164A1 (fr) | 2008-07-01 | 2010-01-06 | Mutabilis | Nouveaux dérivés 1,2,4-triazine et leurs applications biologiques |
| US8877815B2 (en) * | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| EP2925137A1 (fr) * | 2012-11-30 | 2015-10-07 | Bayer CropScience AG | Mélange fongicide ou pesticide binaire |
| GB201704476D0 (en) * | 2017-03-21 | 2017-05-03 | Antabio Sas | Chemical compounds |
| JP7429992B2 (ja) | 2018-09-25 | 2024-02-09 | アンタビオ エスアーエス | 細菌感染の処置における使用のためのインダン誘導体 |
-
2019
- 2019-07-25 JP JP2021540369A patent/JP7429992B2/ja active Active
- 2019-07-25 MX MX2021003498A patent/MX2021003498A/es unknown
- 2019-07-25 CN CN201980063308.1A patent/CN113166084B/zh active Active
- 2019-07-25 KR KR1020217012349A patent/KR20210087025A/ko not_active Application Discontinuation
- 2019-07-25 CN CN201980066561.2A patent/CN113166085B/zh active Active
- 2019-07-25 SG SG11202102791SA patent/SG11202102791SA/en unknown
- 2019-07-25 WO PCT/EP2019/070115 patent/WO2020064173A1/fr unknown
- 2019-07-25 BR BR112021005651-3A patent/BR112021005651A2/pt unknown
- 2019-07-25 US US17/277,649 patent/US20210347748A1/en active Pending
- 2019-07-25 CA CA3113689A patent/CA3113689A1/fr active Pending
- 2019-07-25 AU AU2019351551A patent/AU2019351551A1/en active Pending
- 2019-07-25 MA MA053706A patent/MA53706A/fr unknown
- 2019-07-25 KR KR1020217012348A patent/KR20210087448A/ko not_active Application Discontinuation
- 2019-07-25 WO PCT/EP2019/070116 patent/WO2020064174A1/fr unknown
- 2019-07-25 MX MX2021003485A patent/MX2021003485A/es unknown
- 2019-07-25 BR BR112021005532-0A patent/BR112021005532A2/pt unknown
- 2019-07-25 SG SG11202102790PA patent/SG11202102790PA/en unknown
- 2019-07-25 CA CA3113697A patent/CA3113697A1/fr active Pending
- 2019-07-25 MA MA053707A patent/MA53707A/fr unknown
- 2019-07-25 JP JP2021540370A patent/JP7429993B2/ja active Active
- 2019-07-25 AU AU2019349438A patent/AU2019349438A1/en active Pending
- 2019-07-25 EP EP19744709.7A patent/EP3856729A1/fr active Pending
- 2019-07-25 EP EP19744710.5A patent/EP3856730A1/fr active Pending
- 2019-07-25 US US17/277,535 patent/US20220112169A1/en active Pending
-
2021
- 2021-03-24 IL IL281770A patent/IL281770A/en unknown
- 2021-03-24 CL CL2021000729A patent/CL2021000729A1/es unknown
- 2021-03-24 CL CL2021000731A patent/CL2021000731A1/es unknown
- 2021-03-24 IL IL281780A patent/IL281780A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019351551A1 (en) | 2021-04-15 |
| AU2019349438A1 (en) | 2021-04-15 |
| CL2021000731A1 (es) | 2021-11-05 |
| JP7429993B2 (ja) | 2024-02-09 |
| WO2020064174A1 (fr) | 2020-04-02 |
| IL281770A (en) | 2021-05-31 |
| KR20210087025A (ko) | 2021-07-09 |
| CN113166084B (zh) | 2024-06-04 |
| MA53707A (fr) | 2021-12-29 |
| SG11202102790PA (en) | 2021-04-29 |
| CN113166085B (zh) | 2024-04-09 |
| KR20210087448A (ko) | 2021-07-12 |
| BR112021005532A2 (pt) | 2021-06-29 |
| JP2022502485A (ja) | 2022-01-11 |
| JP2022502486A (ja) | 2022-01-11 |
| US20210347748A1 (en) | 2021-11-11 |
| BR112021005651A2 (pt) | 2021-06-22 |
| CN113166084A (zh) | 2021-07-23 |
| EP3856730A1 (fr) | 2021-08-04 |
| IL281780A (en) | 2021-05-31 |
| EP3856729A1 (fr) | 2021-08-04 |
| MX2021003485A (es) | 2021-09-10 |
| WO2020064173A1 (fr) | 2020-04-02 |
| SG11202102791SA (en) | 2021-04-29 |
| JP7429992B2 (ja) | 2024-02-09 |
| US20220112169A1 (en) | 2022-04-14 |
| CA3113697A1 (fr) | 2020-04-02 |
| CN113166085A (zh) | 2021-07-23 |
| MX2021003498A (es) | 2021-09-10 |
| CA3113689A1 (fr) | 2020-04-02 |
| CL2021000729A1 (es) | 2021-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1063I2 (fr) | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih | |
| MA49760A (fr) | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique | |
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| MA49458A (fr) | Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques | |
| MA50800A (fr) | Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson | |
| MA44734A (fr) | Composés et compositions destinés au traitement d'états associés à une activité de nlrp | |
| MA54515A (fr) | Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires | |
| MA51916A (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| MA55560A (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| MA51677A (fr) | Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
| MA52219A (fr) | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak | |
| MA50155A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une lésion neuronale | |
| MA49906A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| MA40221A (fr) | Dérivés d'isoindoline à utiliser dans le traitement d'une infection virale | |
| MA50233A (fr) | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité | |
| MA44020B1 (fr) | Composés antitumoraux | |
| MA55821A (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| MA43861A (fr) | Inhibiteurs il-8 destinés à être utilisés dans le traitement d'une neuropathie périphérique induite par une chimiothérapie | |
| MA52137A (fr) | Méthodes de traitement de l'amylose ttr à l'aide d'ag10 | |
| MA49524A (fr) | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression | |
| MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate | |
| MA53706A (fr) | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne | |
| MA54290A (fr) | Inhibiteur de kinase aurora a destiné à être utilisé dans le traitement du neuroblastome | |
| MA55507A (fr) | Macitentan destiné à être utilisé dans le traitement de l'hypertension portopulmonaire |